Gastric Cancer
Conditions
Interventions
We measure serum HER2-ECD by the Chemiluminescence immunoassay.
Sponsors
Shizuoka General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histological proven gastric adenocarcinoma. 2)cStage IB/IIA/IIB/IIIA/IIIB/IIIC (except for T1) 3)Patient considered that R(0) resection is possible. 4)Age 20-80 years 5)ECOG PS: 0 or 1 6)No prior treatment 7)Adequate organ functions defined as indicated below (1)WBC >= 2,500 /mm3 (2)Plt >= 100,000 /mm3 (3) T.Bil <= 2.0 mg/dL (4) AST, ALT <= 100 IU/L (5) Cr <= 1.5 mg/dL 8)Written informed consent
Exclusion criteria
Exclusion criteria: 1) Patient with Breast cancer 2) Patient with active double cancer (synchronous double cancer and metachronous double cancer), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment. 3) Patient with severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, or uncontrollable diabetes mellitus, arrhythmias, heart failure, liver cirrhosis, and active hepatitis) 4) Exclude the patients who are recognized as inadequate patients by doctors with responsibility in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interrelationship of serum HER2-ECD with pathological HER2 level. | — |
Countries
Japan
Contacts
Public ContactKeisei Taku
Shizuoka General Hospital Medical Oncology
Outcome results
None listed